Lonza raises full-year core profit margin guidance
22/07/2026 05:41
Lonza raises full-year core profit margin guidance July 22 (Reuters) - Switzerland's Lonza LONN.S, the world's largest contract drug manufacturer, raised the full-year target for its core profit margin to between 33% and 34% on Wednesday, citing strong operational execution and contributions from maturing growth projects.
It had previously expected its core earnings before interest, taxes, depreciation and amortization margin to expand to more than 32% of sales this year.
(Reporting by Bartosz Dabrowski and Kira Britten, editing by Milla Nissi-Prussak)
((bartosz.dabrowski@thomsonreuters.com; +48 58 7696560;))
Recent news on Lonza AG
See all newsLonza buys 5 sites from Germany's Merck to more than double US footprint (updated)
Brief: Merck KGaA Confirms Divestment Of CDMO Business To Lonza
Lonza agrees to buy five US sites from Merck KGaA
Corrected: TABLE-Swiss trade surplus at CHF 4.35 bln in August (Sept. 17)
Table: Swiss trade surplus at CHF 1.31 bln in September